Windtree reports Q3 net loss $3.8M; cash runway only through Jan 2025

WINDTREE THERAPEUTICS INC /DE/

Operating loss $4.7M flat vs Q3 2023; net loss $3.8M ($4.23/share) vs $4.4M ($15.47/share) a year ago.
Cash $2.3M at Sep 30; subsequent ELOC sales raised $2.4M net; funds only through January 2025.
Positive Phase 2b istaroxime data in early cardiogenic shock: primary SBP AUC endpoint met; safety favorable.
July 2024 private placements raised ~$13.9M aggregate ($4.4M new cash, $9.5M debt conversion); $35M ELOC secured.
Nasdaq non-compliance for late 10-Q resolved after filing on Nov 26; listing compliance restored Nov 27.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.